










Introduction. Autoimmune thyroiditis has a high preva-
lence. Clinical manifestations of hypothyroidism due to Hashi-
moto thyroiditis are not always improved by levothyroxine 
treatment, thus causing debate on the clinical approach of 
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mechanisms of autoimmune thyroiditis. Thus, recent data 
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Prezentarea mecanismelor etiopatogenetice contempo-
rane ale tiroiditei autoimune.
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What is not known yet, about the topic 
New data have recently emerged about the etiopathogen-
esis of autoimmune thyroiditis, thus leading to a new diagnos-
tic and therapeutic approach of the patient with Hashimoto’s 
thyroiditis.
Research hypothesis
Presentation of the contemporary etiopathogenetic mecha-
nisms of autoimmune thyroiditis.
ǯ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
The systematization of information on the etiopathogen-
esis of autoimmune thyroiditis has been carried out, with par-
ticular attention given to recent data on the role of TLRs and 
microbiota. A limited number of studies are currently availa-
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Obiectivul acestui articol a fost prezentarea mecanismelor 
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could in the near future change the approaches to proper di-
agnostic tests and treatment principles of the patient with au-
toimmune thyroiditis. In this paper we intend to review the 
literature in terms of mechanisms of development of autoim-
mune thyroiditis. 
Material and methods. The PubMed database was used 
in order to select the data from the literature, using the key-
words ǲon oǳ, ǲǳ, ǲcooǳ. Thus, the 
information containing the data on the etiopathogenesis of au-
toimmune thyroiditis was retained.
Results. Contemporary pathogenetic mechanisms of auto-
immune thyroiditis are molecular mimicry, bystander activa-
tion, and thyroid cell apoptosis. Recent studies highlight the 
role of microbiota and aberrant activation of the innate im-
mune system in the pathogenesis of autoimmune thyroiditis. 
Conclusions. Knowing the new etiopathogenetic mecha-
nisms in autoimmune thyroiditis will in the future provide the 
possibility of a new diagnostic and therapeutic approach of 
the patient with hypothyroidism.
Key words: autoimmune thyroiditis, TLR, microbiota.
Introduction
Autoimmune thyroiditis (AT) is the most common autoim-
mune pathology of the thyroid, characterized by lymphocytic 
ϐȏͳȐǤ
disease are antibodies against thyroid peroxidase and thyro-
globulin. AT may evolve to hypothyroidism, requiring levothy-
roxine substitution treatment. According to Vudu L. (2014), 
2-6% of the population suffer from hypothyroidism [2], reach-
ing up to 9.5% of the adult population, according to Hollowell 
J.  Ǥ [3]. Autoimmune thyroiditis occurs more frequently in 
ǡ͹ǣ͵ȏͶȐǤ
There are several etiopathogenetic mechanisms recog-
nized in AT development, involving both B and T lymphocytes. 
Thyroid cells B lymphocytes are activated and secrete thyroid 
antibodies. Cytokine-secreting T lymphocytes play a role in 
antibody formation, in thyroid cell apoptosis and in regulating 
local immune response [5]. 
The purpose of this article is to present the contemporary 
pathogenetic mechanisms of autoimmune thyroiditis.
Material and methods
The search source was the PubMed online database (Na-
tional Medicine Library of the United States National Insti-
tutes of Health) [6]. The articles were selected based on the 
keywords ǲon oǳ, ǲǳ, ǲcooǳ, pub-
lished during the period 2000-2017. We have also searched 
      ϐ  
search and selected those that were considered relevant. The 
titles that could contain information about autoimmune thy-
roid disease pathogenesis, the role of microbiota and subclini-
ϐ-
itis were retained. The data obtained were systematized and 
analyzed.
70 cn oonc c Án o o on
Results 
Inoon ocn
A number of 312 articles matching the search criteria were 
found in the PubMed database and published between 2000 
and 2017. A number of 123 articles were considered likely to 
be relevant to this review, after the titles analysis. The articles 
in English have been selected. Access to the full test of all ar-
ticles has been obtained. We also looked at the bibliographic 
  ϐ 
those that were considered pertinent. 
Autoimmune thyroiditis is one of the most common causes 
of primary hypothyroidism [7]. It is characterized clinically 
by eu-, hyper- or hypothyroidism, with or without goiter. The 
ϐǡ
includes B and T cells and follicular destruction. Most patients 
have high antibody titers against thyroid antigens. 
Several pathogenetic mechanisms have been described in 
the pathogenesis of AT. Molecular mimicry involves the im-
mune response to a foreign antigen that is structurally similar 
to the endogenous substance. During a bacterial infection, the 
response of the host include antibodies and T cells response 
and a cross reaction with the host’s thermal shock protein 
may occur [8]. If the mimic protein is a thyroid antigen, thy-
roiditis may occur. 
Bystander activation is the detection of a virus in thyroid 
cells, which may cause local cytokine release and activation of 
ϐȏͻȐǤ
Class II HLA antigens are present on follicular thyroid cells 
of patients with AT, but not healthy people, and play the role 
ȏͳͲȐǤϐ
ǣ
 interferon gamma can induce MHC class II molecules on 
thyroid follicular cells [11];
 thyroid follicular cells expressing MHC class II molecules 
may present the viral peptide viruses to cloned human T 
cells [12].
Apoptosis of thyroid cells is the primary pathological phe-
nomenon of AT. Normal thyroid epithelial cells express the Fas 
apoptosis receptor, activation of which could contribute to the 
destruction of AT characteristic follicular cells [13]. IL-1 pro-
duced by T cells induces expression of the Fas ligand and thus 
causes auto-apoptosis [14].
AT triggers are excessive iodine intake [15], some drugs 
and infections [16], fetal microchimerism [17], pregnancy and 
female sex [18], stress, genetic susceptibility [19].
Despite the high prevalence, the etiopathogenetic mecha-
nisms of the disease are not fully elucidated. In recent years, 
there is growing evidence of new mechanisms involved in AT 
pathogenesis, such as the role of the microbiota and the role of 
TLRs. Recent studies have demonstrated the role of aberrant 
activation of the innate immune system in the pathogenesis of 
AT. TLR is a family of 10 cell surface receptors, which together 
with IL-1 receptors form the superfamily of the nnǦ1 
co Ȁ oǦ co [20]. TLRs are so named for their 
similarity to Toll, a oo receptor that is crucial in pro-
tecting against fungal infection [21]. These receptors protect 

Pc noì













cut de anticorpi împotriva antigenilor tiroidieni.
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tiroidita.  
Activarea martorului este detectarea unui virus în celulele 
ǡ£è
ϐȏͻȐǤ
Antigenele HLA clasa II sunt prezente pe celulele tiroidiene 
ìǡè££ǡè
rolul de celule prezentatoare de antigen [10]. Câteva consta-
£ì££ǣ
 interferonul gamma poate induce moleculele MHC clasa 
II pe celulele foliculare tiroidiene [11];
   ǡ  £ 
MHC de clasa II, pot prezenta antigenele peptidice virale 
celulelor T umane clonate [12].
Apoptoza celulelor tiroidiene este fenomenul patologic 
principal din TA.









ale maladiei nu sunt pe deplin elucidate. 
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tru similitudinea lor cu Toll, un receptor al Drosophilei, care 
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din organele limfoide [25]. Recent, TLR3 au fost descrise pe 
celulele nonimune, în asociere cu maladiile autoimune. TLR3 




croorganismelor comensale nepatogene în dezvoltarea tiroi-
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£ϐ-
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conduce la distrugerea barierei mucoase intestinale, ducând 
è-
 èǡ ǡ   £ 
ȏ͵ͳȐǤ    ǡ  ǡ   ì
ǣB, o, o n co 1, oǦ
, Ec  o, Ec nn oǦ
, o, Bccocc, Sococc, 	cnc, 









ì	c, nococc o, Sococcè
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mammalian microorganisms, causing innate immune system 
response [22]. Immune innate response activates genes for 
ϐ-
  Ǧϐ  ǡ ǡ 
well as cellular [23]. TLRs are present in monocytes, macro-
phages, immune cells. TLR3, mediating the antiviral response 
ȏʹͶȐǡ       Ȃ 
presenting cells that process, then present antigenic peptides 
to lymphoid cells from lymphoid organs [25]. Recently, TL3 
have been described on non-immune cells in association with 
autoimmune diseases. TLR3 in pancreatic beta cells are in-
volved in the pathogenesis of insulitis and type 1 diabetes [26] 
and, more recently, in autoimmune thyroiditis [27]. 
A growing body of evidence suggests the involvement of 
non-pathogenic commensal microorganisms in the develop-
Ǧϐ
immune responses in the host. Studies show the critical role 
of commensal intestinal microbiota in the development of au-
toimmune diseases. The intestinal microbiota is composed of 
over 1200 species of anaerobic and aerobic bacteriophages, 
viruses and fungi [28]. This bacterial population is predomi-
nantly represented by the species Bco, 	c, 
cnoc, Pooc and coco. A recent 
study in o shows that HT patients have a more diverse 
ȋȽǦȌ-
dividuals [29]. 	c was more abundant and BcoǦ
 less abundant, which is characteristic for healthy host’s 
microbiota, but also occurs in obesity and in subjects with ir-
ritable bowel syndrome [30]. According to the results of the 
same study, Pco and Po were low in 
patients with AT. In previous studies, it has been found out that 
these species play an important role in maintaining human 
health. Therefore, in patients with AT, their low levels can lead 
to the destruction of the intestinal mucosa barrier, leading to 
the translocation of bacteria and their products via the muco-
sal barrier and, consequently, to the activation of the immune 
response [31]. Other species were also higher in patients with 
ǣB, o, o n co 1, o, 
Ec  o, Ec nn o, 
o, Bccocc, Sococc, 	cnc, nǦ
o, oo, oococc ͸ and Son 
[29]. In previous studies, the high abundance of these species 
ϐ
diseases. Intestinal dysbiosis is noted in multiple sclerosis [32, 
33], type 1 diabetes [34, 35, 36], rheumatic diseases [37, 38] 
and obesity [39, 40, 41].
Interestingly, changes in intestinal microbiota are similar 
in patients with IBS and AT. Several recent microbiota stud-
ies in IBS patients reported increases in the abundance of 	Ǧ
c, nococc o, Sococc and cnoǦ
c, and abundance was positively correlated with intesti-
nal symptoms [44, 45]. 
Intra-thyroid homeostasis and peripheral iodothyronines 
depend to a large extent on the function of enzymes, ion 
pumps, transporters whose activity is modulated by iodothy-
ǡǣ
iodine and selenium.
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varea martorului, apoptoza celulelor tiroidiene sunt mecanis-
ÁìèǤ-
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 Á£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Á
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Selenium is a mandatory constituent of selenoproteins 
[46], among which deiodinases, which regulate peripheral 
thyroid homeostasis [47]. Absorption of selenium occurs in 
the duodenum and at the level of the cecum and may vary de-
pending on its chemical form [48]. The thyroid has the highest 
selenium content per gram of whole body tissue [49]. It has 
been determined that some intestinal bacteria, such as EcǦ
c co, o and Enoc, are carriers of genes 
encoding selenoproteins [50].
In a recent study [51], it has been shown that selenium, 
which is not absorbed in the small intestine, can be actively 
taken up in the colon and metabolized by the microbiota, 
representing a competition for the substrate, which results in 
a reduction in bioavailability of selenium, as evidenced by the 
inverse effect of an inactive microbiota [51]. Thus, bacteria can 
compete with the host, especially in the presence of a limited 
amount of selenium, and the increase in selenium uptake by 
    ϐ   
selenoproteins in the host [52].
Discussion
Autoimmune thyroiditis is the most prevalent autoimmune 
disease [53] and the most common cause of hypothyroidism 
[54]. It is diagnosed based on clinical, ultrasonographic data 
and the presence of antibodies against thyroid antigens. Most 
patients have increased antibody titers against thyroid peroxi-
dase. Current treatment of hypothyroidism due to Hashimoto 
thyroiditis is based on the administration of synthetic thyroid 
hormones, which does not always alleviate the symptoms of 
the patient. In the etiopathogenesis of autoimmune thyroid-
itis, both genetic and non-genetic factors are involved. Molec-
ular mimicry, bystander activation, thyroid cell apoptosis are 
mechanisms that play a role in the development of Hashimo-
to’s thyroiditis. Recent studies have demonstrated the role of 
aberrant activation of the innate immune system in AT patho-
genesis [31]. The intestinal microbiota and non-pathogenic 
commensal microorganisms are involved in the development 
Ǧϐ
host [31]. The new etiopathogenetic mechanisms researched 
in recent years, involving intestinal microbiota and TLRs, will 
allow the development of new treatments based on mecha-
nisms rather than clinical manifestations. 
Conclusions
Recent studies suggest that microbiota and aberrant ac-
tivation of the innate immune system play a special role in 
the pathogenesis of autoimmune thyroiditis in subjects with 
genetic predisposition. A limited number of studies have ap-
proached these interrelations, and more research is needed to 
ϐ-
tic and treatment strategies to be implemented.
ϐ
ϐǤ
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